The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration

Nephrology Dialysis Transplantation

Volumn 27, Issue 8, 2012, Pages 3110-3119

  Yu, Xiaofang ^a   Fang, Yi ^a   Liu, Hong ^a   Zhu, Jiaming ^a   Zou, Jianzhou ^a   Xu, Xunhui ^a   Jiang, Suhua ^a   Ding, Xiaoqiang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

chronic kidney disease; HIF ; L mimosine; timing

Indexed keywords

ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; ERYTHROPOIETIN; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; ISOPROTEIN; MESSENGER RNA; MIMOSINE; SMAD3 PROTEIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD31 GENE; CELL INFILTRATION; CHRONIC KIDNEY DISEASE; COLLAGEN METABOLISM; COLLAGEN TYPE 3 GENE; CONNECTIVE TISSUE GROWTH FACTOR GENE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ERYTHROPOIETIN GENE; GENE; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE TARGETING; GLOMERULUS CAPILLARY; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY INTERSTITIUM; KIDNEY STRUCTURE; KIDNEY TUBULE PRESSURE; MACROPHAGE; MALE; NONHUMAN; PGK1 GENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TREATMENT DURATION; UPREGULATION; URINE LEVEL; VASCULOTROPIN GENE;

ACTINS; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CAPILLARIES; COLLAGEN TYPE III; DIOXYGENASES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FIBROSIS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY TUBULES; MALE; MIMOSINE; NEPHRECTOMY; RATS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY, CHRONIC; RNA, MESSENGER;

EID: 84864612843     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr754     Document Type: Article

References (39)

1. Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl 2000; 75: S22-S26.
2. Kang DH, Kanellis J, Hugo C et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002; 13: 806-816.
3. Eckardt KU, Rosenberger C, J̈urgensen JS et al. Role of hypoxia in the pathogenesis of renal disease. Blood Purif 2003; 21: 253-257.
4. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25.
5. Semenza GL, Agani F, Booth G et al. Structural and functional analysis of hypoxia-inducible factor. 1 Kidney Int 1997; 51: 553-555.
6. Bernhardt WM, Warnecke C, Willam C et al. Organ protection by hypoxia and hypoxia-inducible factors. Methods Enzymol 2007; 435: 221-245.
7. Loboda A, Jozkowicz A, Dulak J. HIF-1 and HIF-2 transcription factors-similar but not identical. Mol Cells 2010; 29: 435-442.
8. Rosenberger C, Rosen S, Heyman SN. Current understanding of HIF in renal disease. Kidney Blood Press Res 2005; 28: 325-340.
9. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294: 1337-1340.
10. Ivan M, Kondo K, Yang H et al. HIFalpha targeted for VHLmediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292: 464-468.
11. Jaakkola P, Mole DR, Tian YM et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-472.
12. Warnecke C, Griethe W, Weidemann A et al. Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J 2003; 17: 1186-1188.
13. Smith TG, Talbot NP. Prolyl hydroxylases and therapeutics. Antioxid Redox Signal 2010; 12: 431-433.
14. Li N, Yi F, Sundy CM et al. Expression and actions of HIF prolyl-4- hydroxylase in the rat kidneys. Am J Physiol Renal Physiol 2007; 292: F207-F216.
15. Hill P, Shukla D, Tran MG et al. Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 2008; 19: 39-46.
16. Tanaka T, Kojima I, Ohse T et al. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab Invest 2005; 85: 1292-1307.
17. Song YR, You SJ, Lee YM et al. Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney. Nephrol Dial Transplant 2010; 25: 77-85.
18. Tanaka T, Matsumoto M, Inagi R et al. Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis. Kidney Int 2005; 68: 2714-2725.
19. Ohtomo S, Nangaku M, Izuhara Y et al. Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model. Nephrol Dial Transplant 2008; 23: 1166-1172.
20. Higgins DF, Biju MP, Akai Y et al. Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Renal Physiol 2004; 287: F1223-F1232.
21. Higgins DF, Kimura K, Bernhardt WM et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 2007; 117: 3810-3820.
22. Higgins DF, Kimura K, Iwano M et al. Hypoxia-inducible factor signaling in the development of tissue fibrosis. Cell Cycle 2008; 7: 1128-1132.
23. Kimura K, Iwano M, Higgins DF et al. Stable expression of HIF- 1alpha in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol 2008; 295: F1023-F1029.
24. Yu X, Fang Y, Ding X et al. Transient hypoxia-inducible factor activation in rat renal ablation and reduced fibrosis with L-mimosine. Nephrology (Carlton) 2012; 17: 58-67.
25. Kren S, Hostetter TH. The course of the remnant kidney model in mice. Kidney Int 1999; 56: 333-337.
26. Jiang S, Chen Y, Zou J et al. Diverse effects of ischemic pretreatments on the long-term renal damage induced by ischemia-reperfusion. Am J Nephrol 2009; 30: 440-449.
27. Li HY, Hou FF, Zhang X et al. Advanced oxidation protein products accelerate renal fibrosis in a remnant kidney model. J Am Soc Nephrol 2007; 18: 528-538.
28. Siddiq A, Aminova LR, Ratan RR. Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress. Neurochem Res 2007; 32: 931-946.
29. Willam C, Maxwell PH, Nichols L et al. HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J Mol Cell Cardiol 2006; 41: 68-77.
30. Stiehl DP, Wirthner R, Koditz J et al. Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system. J Biol Chem 2006; 281: 23482-23491.
31. Appelhoff RJ, Tian YM, Raval RR et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004; 279: 38458-38465.
32. Masson N, Willam C, Maxwell PH et al. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001; 20: 5197-5206.
33. Schodel J, Klanke B, Weidemann A et al. HIF-prolyl hydroxylases in the rat kidney: physiologic expression patterns and regulation in acute kidney injury. Am J Pathol 2009; 174: 1663-1674.
34. Scortegagna M, Ding K, Zhang Q et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 2005; 105: 3133-3340.
35. Bahlmann FH, Song R, Boehm SM et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110: 1006-1012.
36. Warnecke C, Zaborowska Z, Kurreck J et al. Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF- 2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J 2004; 18: 1462-1464.
37. Raval RR, Lau KW, Tran MG et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel- Lindau-associated renal cell carcinoma. Mol Cell Biol 2005; 25: 5675-5686.
38. Semenza GL, Roth PH, Fang HM et al Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor. 1 J Biol Chem 1994 269 23757-23763.
39. Basu RK, Hubchak S, Hayashida T et al. Interdependence of HIF- 1? and TGF-?/Smad3 signaling in normoxic and hypoxic renal epithelial cell collagen expression. Am J Physiol Renal Physiol 2011; 300: F898-F905